Garry A. Neil, M.D. is the President and Chief Executive Officer of Avalo Therapeutics, a biotech firm focused on bringing innovative treatments to market. He stepped into this role on February 14, 2022, after serving as Chief Scientific Officer and...

Garry A. Neil, M.D. is the President and Chief Executive Officer of Avalo Therapeutics, a biotech firm focused on bringing innovative treatments to market. He stepped into this role on February 14, 2022, after serving as Chief Scientific Officer and Chief Medical Officer for the company in the lead-up to his appointment. Before Avalo, Dr. Neil had an extensive career in the pharmaceutical industry, holding senior leadership positions at major companies like Johnson & Johnson and AstraZeneca. He also has a strong background in life sciences private equity as a partner at Apple Tree Partners. Dr. Neil earned both his B.S. and M.D. from the University of Saskatchewan and completed further training in internal medicine and gastroenterology at the University of Toronto. Under his leadership, Avalo Therapeutics is navigating exciting developments in biopharmaceuticals, aiming to address complex health issues. Known for having led the development of several significant therapies, his experience and expertise drive Avalo towards its mission of improving patient health through innovative science.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Avalo Therapeutics CEOs

A

Garry A. Neil

CEO of Avalo Therapeutics

Education

B.S. and M.D. from the University of Saskatchewan College of Medicine

Field of Expertise

Healthcare & Life Sciences - Medicine

Sector of Economy

Healthcare

CEO of Avalo Therapeutics for

3 years 1 month (Feb 2022 - Present)

Previous Experience

Chief Scientific Officer of Aevi Genomic Medicine, Inc.

Rivals

Competitors/colleagues of Garry A. Neil

Holdings

See how much did Garry A. Neil make over time.

Dr. Garry A. Neil's key financial interests currently lie with Avalo Therapeutics, where his compensation in 2023 was reported at $641,250, including a salary of $475,000 and a bonus of $166,250. Notably, he hasn't vested any stock options yet, indicating...

Dr. Garry A. Neil's key financial interests currently lie with Avalo Therapeutics, where his compensation in 2023 was reported at $641,250, including a salary of $475,000 and a bonus of $166,250. Notably, he hasn't vested any stock options yet, indicating that his compensation relies more on cash rewards tied to performance. In 2022, his total compensation was slightly lower at $601,900, showing an upward trend in his earning potential as the company navigates its biopharma challenges. Before his role at Avalo, he was Chief Scientific Officer at Aevi, which merged with Avalo. His financial stakes reflect a belief in the company’s future, crucial as it seeks successful outcomes in treatments they are developing. So far, Dr. Neil’s role has been pivotal in steering Avalo’s innovative strategies towards addressing unmet health needs, which in turn defines his personal investment success.

Insider Trading

See recent insider trades of Garry A. Neil.

AVTX

$13.68K

AVTX at $3.42/share

Jun 9, 2023

Purchase

AVTX

$9.21K

AVTX at $4.42/share

Dec 9, 2022

Purchase

AVTX

$6.70K

AVTX at $1.57/share

Dec 10, 2021

Purchase

Compensation History

See how much did Garry A. Neil make over time.

For the fiscal year 2023, Garry A. Neil, M.D. earned a total compensation of $641,250. His salary was set at $475,000, complemented by a bonus of $166,250 that reflects his performance in achieving company goals. This represents a notable increase from his 2022 total of $601,900, driven largely by his impactful leadership role at Avalo Therapeutics. Additionally, in 2023, there were no stock options or other compensations reported, highlighting a focus on cash-based earnings aligned with company performance metrics. The structure of his compensation is aimed at incentivizing strong results while retaining top executive talent, aligning with broader strategies in the biotech sector. Overall, Dr. Neil's compensation reflects both his significant experience in the pharmaceutical industry and his commitment to driving Avalo's mission and performance.

Year

2023

Total Compensation

$641.25K

Salary

$475.00K

Board Justification

The compensation philosophy of the company for the CEO in 2023 is to align compensation with company performance, peer benchmarking, and retention strategies, with a focus on motivating executives to achieve both short- and long-term results that benefit stockholders.

Bonus

$166.25K

Board Justification

The amounts reflect the discretionary annual bonus earned for the given fiscal year based on the achievement of goals as recommended by the Compensation Committee and approved by the Board. The bonus is typically paid in the year following the year it was earned. In June 2024, the Compensation Committee recommended and the Board approved bonuses for fiscal year 2023 payable to Dr. Neil based on 50% achievement of predetermined corporate and individual goals.

Other

$0.00

Board Justification

No other compensation was reported for 2023.

Restricted Stock

$0.00(0 common stock)

Board Justification

No stock grants were reported as vested in 2023.

Performance Metrics

The performance metrics of the company for the CEO that determines the compensation in 2023 include achievement of predetermined corporate and individual goals.

Other Avalo Therapeutics CEOs

Here are other CEOs of Avalo Therapeutics

Michael Cola

Ex-CEO of Avalo Therapeutics

February 2020 - February 2022